Corbus Pharmaceuticals (CRBP)
(Delayed Data from NSDQ)
$18.78 USD
+0.46 (2.51%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $18.98 +0.20 (1.06%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.78 USD
+0.46 (2.51%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $18.98 +0.20 (1.06%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
Zacks News
After Plunging 29.4% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Corbus Pharmaceuticals (CRBP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Jazz Pharma (JAZZ) Begins Zepzelca Confirmatory Study for SCLC
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) and partner PharmaMar initiate a late-stage study to evaluate Zepzelca in metastatic SCLC. Data from the study will support full approval of the drug for the indication.
Down 31.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Corbus Pharmaceuticals (CRBP)
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Will Corbus Pharmaceuticals (CRBP) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -25.00% and -83.57%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Corbus Pharmaceuticals (CRBP) Stock?
by Zacks Equity Research
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
Do Options Traders Know Something About Corbus Pharmaceuticals (CRBP) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Corbus Pharmaceuticals (CRBP) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cannabis ETF Tops in January: 5 Stocks That Led the Way
by Sweta Killa
Inside the top performing stocks in the top ETF of January.
Corbus Pharmaceuticals (CRBP) Catches Eye: Stock Jumps 7.3%
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Implied Volatility Surging for Corbus Pharmaceuticals (CRBP) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Corbus (CRBP) Stock?
by Zacks Equity Research
Investors need to pay close attention to Corbus (CRBP) stock based on the movements in the options market lately.
Corbus Pharmaceuticals (CRBP) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -4.88% and -64.01%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Aurora Cannabis (ACB) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Aurora Cannabis' (ACB) fiscal first-quarter results are likely to reflect solid prospects in the Canadian market.
Corbus Pharmaceuticals (CRBP) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Corbus Stock Down as Lenabasum Fails to Meet Primary Endpoint
by Zacks Equity Research
Corbus (CRBP) releases disappointing top-line results from its 28-week phase IIb study of lenabasum in patients with cystic fibrosis.
Are Options Traders Betting on a Big Move in Corbus (CRBP) Stock?
by Zacks Equity Research
Investors need to pay close attention to Corbus (CRBP) stock based on the movements in the options market lately.
Implied Volatility Surging for Corbus Pharmaceuticals (CRBP) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Corbus Pharmaceuticals (CRBP) Stock?
by Zacks Equity Research
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Corbus Pharmaceuticals (CRBP) Stock?
by Zacks Equity Research
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
Is Corbus Pharmaceuticals (CRBP) Stock a Solid Choice Right Now?
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Corbus Pharmaceuticals (CRBP) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.